Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.

Abstract

PURPOSE:

To test the hypothesis that increased pelvic bone marrow (BM) irradiation is associated with increased hematologic toxicity (HT) in cervical cancer patients undergoing chemoradiotherapy and to develop a normal tissue complication probability (NTCP) model for HT.

METHODS AND MATERIALS:

We tested associations between hematologic nadirs during chemoradiotherapy and the volume of BM receiving≥10 and 20 Gy (V10 and V20) using a previously developed linear regression model. The validation cohort consisted of 44 cervical cancer patients treated with concurrent cisplatin and pelvic radiotherapy. Subsequently, these data were pooled with data from 37 identically treated patients from a previous study, forming a cohort of 81 patients for normal tissue complication probability analysis. Generalized linear modeling was used to test associations between hematologic nadirs and dosimetric parameters, adjusting for body mass index. Receiver operating characteristic curves were used to derive optimal dosimetric planning constraints.

RESULTS:

In the validation cohort, significant negative correlations were observed between white blood cell count nadir and V10 (regression coefficient (β)=-0.060, p=0.009) and V20 (β=-0.044, p=0.010). In the combined cohort, the (adjusted) β estimates for log (white blood cell) vs. V10 and V20 were as follows: -0.022 (p=0.025) and -0.021 (p=0.002), respectively. Patients with V10≥95% were more likely to experience Grade≥3 leukopenia (68.8% vs. 24.6%, p<0.001) than were patients with V20>76% (57.7% vs. 21.8%, p=0.001).

CONCLUSIONS:

These findings support the hypothesis that HT increases with increasing pelvic BM volume irradiated. Efforts to maintain V10<95% and V20<76% may reduce HT.

• Authors: Brent S Rose, Bulent Aydogan, Yun Liang, Mete Yeginer, Michael D Hasselle, Virag Dandekar, Rounak Bafana, Catheryn M Yashar, Arno J Mundt, John C Roeske, Loren K Mell
• Journal: International journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 79 Issue 3 Pg. 800-7 (Mar 01 2011) ISSN: 1879-355X [Electronic] United States
• PMID: 20400238 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Validation Study)
• Copyright: Copyright © 2011 Elsevier Inc. All rights reserved.

Chemical References

• Antineoplastic Agents
• Hemoglobin A
• Cisplatin

Topics

• Antineoplastic Agents (adverse effects, therapeutic use)
• Body Mass Index
• Bone Marrow (drug effects, radiation effects)
• Cisplatin (administration & dosage, therapeutic use)
• Combined Modality Therapy (adverse effects, methods)
• Female
• Hemoglobin A (analysis)
• Humans
• Leukocyte Count
• Middle Aged
• Models, Statistical
• Neutrophils (drug effects, radiation effects)
• Organs at Risk (radiation effects)
• Pelvis
• Platelet Count
• Probability
• Radiation Injuries (complications)
• Radiotherapy Dosage
• Radiotherapy, Intensity-Modulated (adverse effects)
• Uterine Cervical Neoplasms (blood, drug therapy, radiotherapy)